Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) from a boosted protease inhibitor-based regimen

被引：0
|
作者：
Rockstroh, J. [1 ]
Molina, J. M. [2 ]
Post, F. [3 ]
Fox, J. [4 ]
Koenig, E. [5 ]
Daar, E. S. [6 ]
Ruane, P. [7 ]
Crofoot, G. [8 ]
Oguchi, G. [9 ]
Creticos, C. [10 ]
Liu, A. [11 ]
Andreatta, K. [11 ]
Graham, H. [11 ]
Brainard, D. [11 ]
Martin, H. [11 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Hop St Louis, Paris, France
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Inst Dominicano Estudios Virol IDEV, Santo Domingo, Dominican Rep
[6] Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA 90509 USA
[7] Ruane Clin Res Grp Inc, Los Angeles, CA USA
[8] Crofoot Res Ctr, Houston, TX USA
[9] Midland Florida Clin Res Ctr, Deland, FL USA
[10] Howard Brown Hlth Ctr, Chicago, IL USA
[11] Gilead Sci Inc, Foster City, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O005
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [11] Phase 3, randomised, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: a sub-analysis of week-48 lipid results
    Fox, J.
    Post, F. A.
    Johnson, M.
    Daar, E. S.
    DeJesus, E.
    Liu, Y-P
    Graham, H.
    Cheng, A.
    Martin, H.
    Quirk, E.
    HIV MEDICINE, 2018, 19 : S84 - S85
  • [12] Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Hagins, D.
    Koenig, E.
    Avihingsanon, A.
    Chetchotisakd, P.
    Supparatpinyo, K.
    Gankina, N.
    Pokrovsky, V.
    Voronin, E.
    Stephens, J. L.
    DeJesus, E.
    Wang, H.
    Acosta, R.
    Brainard, D.
    Martin, H.
    Makadzange, T. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 4 - 4
  • [13] Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up
    Lanzafame, Massimiliano
    Lattuada, Emanuela
    Delama, Andrea
    Mori, Giovanni
    Vento, Sandro
    BIOMEDICINES, 2024, 12 (11)
  • [14] Week 48 outcomes from the BRAAVE 2020 study: a randomised switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in African American adults with HIV
    Hagins, D.
    Kumar, P.
    Wurapa, A.
    Brar, I.
    Berger, D.
    Osiyemi, O.
    Hileman, C.
    Ramgopal, M.
    McDonald, C.
    Blair, C.
    Andreatta, K.
    Collins, S. E.
    Brainard, D.
    Gohlar, G.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 33 - 34
  • [15] Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
    Ranzenigo, Martina
    Gianotti, Nicola
    Galli, Laura
    Poli, Andrea
    Mastrangelo, Andrea
    Bruzzesi, Elena
    Chiurlo, Matteo
    Nozza, Silvia
    Bossolasco, Simona
    Spagnuolo, Vincenzo
    Mancusi, Daniela
    Termini, Roberta
    Carini, Elisabetta
    Lazzarin, Adriano
    Castagna, Antonella
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1975 - 1982
  • [16] ECONOMIC IMPACT OF RAPID TREATMENT INITIATION OF HIV WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) FROM A CANADIAN HEALTHCARE PERSPECTIVE
    Guinan, K.
    Mathurin, K.
    Lachaine, J.
    VALUE IN HEALTH, 2023, 26 (06) : S184 - S185
  • [17] Restarting bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: A pooled analysis of studies in people with HIV-1
    Pozniak, A.
    Orkin, C.
    Maggiolo, F.
    Yazdanpanah, Y.
    Baumgarten, A.
    Mounzer, K.
    D'Antoni, M. L.
    Huang, H.
    Liu, H.
    Andreatta, K.
    VanderVeen, L.
    Callebaut, C.
    Hindman, J. T.
    Martin, H.
    Arribas, J. R.
    HIV MEDICINE, 2023, 24 : 195 - 196
  • [18] High prevalence of previously undocumented baseline M184V/I does not affect virologic outcome in virologically-suppressed patients switching to bictegravir/emtricitabine/tenofovir alafenamide from a boosted protease inhibitor-based regimen
    Andreatta, K.
    Haubrich, R.
    Willkom, M.
    Martin, R.
    Chang, S.
    Acosta, R.
    Liu, Y.
    Graham, H.
    Quirk, E.
    White, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [19] Sustained viral suppression after switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among clinical trial participants with preexisting M184V/I
    Rockstroh, Juergen
    Andreatta, Kristen
    Acosta, Rima
    D'Antoni, Michelle L.
    Porter, Danielle P.
    Chang, Silvia
    Martin, Ross
    Willkom, Madeleine
    McNicholl, Ian
    Gallant, Joel
    Graham, Hiba
    Collins, Sean
    Martin, Hal
    White, Kirsten L.
    INFECTION, 2021, 49 (SUPPL 1) : S18 - S19
  • [20] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
    Acosta, Rima K.
    Willkom, Madeleine
    Andreatta, Kristen
    Liu, Hui
    Martin, Ross
    Parvangada, Aiyappa
    Martin, Hal
    Collins, Sean
    White, Kirsten L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
12345